Domaine de Maîtrise :
Biopathologie et Recherche Biomédicale

Domaine d’intérêt :
Recherche Clinique, Biopathologie et Recherche Biomédicale**

Les publications :
1. Synthesis and biological evaluation of ethacrynic acid derivatives bearing sulfonamides as potent anti-cancer agents,El Abbouchi, A.; El Brahmi, N.; Hiebel, M-A.; Bignon, J.; Guillaumet, G.; Suzenet, F.; El Kazzouli, S. Bioorg. Med. Chem. Lett. 2020, 30, 127426. (IF = 2.7). 2. Exploration of biomedical dendrimer space based on in-vitro physicochemical parameters: key factor analysis (Part 1). Mignani, S.; Rodrigues, J.; Roy, R.; Shi, X.; Cenã, V.; El Kazzouli, S.; Majoral. J-P. Drug Discov. Today, 2019, 24, 1176. (IF = 6.88). 3. Exploration of biomedical dendrimer space based on in-vitro physicochemical parameters: key factor analysis (Part 2). Mignani, S.; Rodrigues, J.; Roy, R.; Shi, X.; Cenã, V.; El Kazzouli, S.; Majoral. J-P. Drug Discov. Today, 2019, 24, 1184. (IF = 6.88). 4. Original Multivalent Gold(III) and Dual Gold(III)–Copper(II) Conjugated Phosphorus Dendrimers as Potent Antitumoral and Antimicrobial Agents, Mignani, S.; El Brahmi, N.; El Kazzouli, S.; Laurent, R.; Ladeira, S.; Caminade, A-M.; Pedziwiatr-Werbicka, E.; Szewczyk, E. M.; Bryszewska, M.; Bousmina, M.; Cresteil, T.; Majoral, J-P. Molecular Pharmaceutics. 2017, 14, 4087. (IF = 4.44) 5. Anticancer copper(II) phosphorus dendrimers are potent proapoptotic Bax activators. Mignani, S. El Brahmi, N.; Eloy, L.; Poupon, J.; Nicolas, V.; Steinmetz, A.; El Kazzouli, S.; Bousmina, M. ; Blanchard-Desce, M.; Caminade, A-M.; Majoral, J-P.; Cresteil, T. Eur. J. Med. Chem. 2017, 132, 142. (IF = 4.5) 6. Symmetrical and unsymmetrical incorporation of active biological monomers on the surface of phosphorus dendrimers. El Brahmi, N.; El Kazzouli, S.; Mignani, S.; Laurent. R.; Ladeira. S.; Caminade, A-M.; Bousmina, M.; Majoral, J-P. Tetrahedron. 2017, 73, 1331. (IF = 2.64) 7. A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action. Mignani, S. El Brahmi, N. El Kazzouli, S.: Eloy, L.; Courilleau, D.; Caron, J. S. Bousmina, M. Caminade, A-M. Cresteil, T. Majoral, J-P. Eur. J. Med. Chem. 2016, 122, 656. (IF = 4.5) 8. Investigations in dendrimer space reveal solid and liquid tumor growth-inhibition by original phosphorus-based dendrimers and corresponding monomers and dendrons with ethacrynic acid motifs. El Brahmi, N.; Mignani, S.; Caron, J.; El Kazzouli, S.; Bousmina, M.; Caminade, A- M.; Cresteil, T.; Majoral, J-P. Nanoscale, 2015, 7, 3915. (IF = 7.4) 9. Dendrimer Space Exploration: Inhibition of protein-protein interactions for the next generation of pharmaceuticals. Mignani, S.; El Kazzouli, S.; Bousmina, M.; Majoral, J-P. Chem. Rev. 2014, 114, 1327. (IF = 48) 10. Dendrimer space concept for innovative nanomedicine: a futuristic vision in medicinal chemistry. Mignani, S.; El Kazzouli, M.; Bousmina, M.; Majoral, Progress in Polymer Science, 2013, 38, 993. (IF = 26.84) 11. Original multivalent copper(II)-conjugated phosphorus-dendrimers and corresponding mononuclear copper(II) complexes with anti-tumoral activities. El Brahmi, N. El Kazzouli, S. Mignani, S. Essassi, E. Aubert, G. Laurent, R. Caminade, A-M. Bousmina, M. Cresteil, T. Majoral, J-P. Molecular Pharmaceutics, 2013, 10, 1459. (IF = 4.4) 12. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. Mignani, S.; El Kazzouli, M.; Bousmina, M.; Majoral, J-P. Advanced Drug Delivery Reviews, 2013, 65, 1316. (IF = 12) 13. From Metallodrugs to Metallodendrimers for Nanotherapy in Oncology: a Concise Overview. El Kazzouli, S.; El Brahmi, N.; Mignani, S.; Bousmina, M.; Zablocka, M.; Majoral, J-P. Current Med. Chem. 2012, 4995. (IF = 3.85) 14. Molecular basis for the failure of the "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol ester. Gerzy, T.; Peach, M. L.; El Kazzouli, S.; Sigano, D. M.; Lewin N. E.; Marquez, V. E.; Blumberg, P. M. J. Bio. Chem. 2012, 287, 13137. (IF = 4.4) 15. Dendrimer therapeutics: covalent and ionic attachments. El Kazzouli, S.; Mignani, S.; Bousmina, M.; Majoral, J-P.; New J. Chem. 2012, 36, 227. (IF = 3.08) 16. N-methyl-substituted fluorescent DAG–indololactone isomers exhibit dramatic differences in membrane interactions and biological activity. Gal N.; Kolusheva S.; Kedei N.; Telek A.; Naeem T. A.; Lewin N. E.; Lim, L.; Mannan P.; Garfield S. H.; El Kazzouli, S.; Sigano, D. M.; Marquez, V. E.; Blumberg, P. M.; Jelinek R. ChemBioChem. 2011, 12, 2331. (IF = 3.09) 17. Membrane-surface anchoring of charged diacylglycerol-lactones correlates with biological activities. Raifman, O.; Kolusheva, S.; El Kazzouli, S.; Sigano, D. M.; Kedei, N.; Lewin, N. E.; Lopez-Nicolas, R.; Ortiz-Espin, A.; Gomez-Fernandez, J. C.; Blumberg, P. M.; Marquez, V. E.; Corbalan-Garcia, S.; Jelinek. R. ChemBioChem. 2010 11, 2003. (IF = 3.09) 18. Conformationally constrained analogues of diacylglycerol. 30. An investigation of diacylglycerol-lactones containing heteroaryl groups reveals compounds with high selectivity for Ras Guanyl Nucleotide-Releasing Proteins. El Kazzouli, S.; Lewin, N. E.; Blumberg, P. M.; Marquez V. E. J. Med. Chem., 2008, 51, 5198. (IF = 5.45) 19. Conformationally constrained analogues of diacylglycerol (DAG). 29. Cells sort DAG- lactone chemical zip codes to produce diverse and selective biological activities. Duan, D.; Sigano, D. M.; Kelley, J. A.; Lai, C.; Lewin, N. E.; Kedei, N.; Peach, M. L.; Lee, J.; Abeyweera, P. T.; Rotenberg A. S.; Kim, H.; Kim, H. Y.; El Kazzouli S.; Chung, J-U.; Howard Y. A.; Matthew Y. R.; Alyson B.; Colburn N. H.; Friedman, A. H.; Truman, P. J.; Parrish D. H.; Deschamps J. R.; Perry, N. A.; Surawski, J. R.; Blumberg, P. M.; Marquez, V. E. J. Med. Chem., 2008, 51, 5371. (IF = 5.45)